AstraZeneca Pharma India logo

AstraZeneca Pharma India MD, chairman, board of directors and AGM

NSE: ASTRAZENBSE: 506820Pharmaceuticals & BiotechnologySmall Cap

Formerly Astra IDL
Last close ₹5,988.50down ₹112.50 (1.84%)BSE ₹5,988.15

Share price at the NSE close on 23 Oct 2026. Previous close ₹6,101.00.

52-week range of traded prices to 23 Oct 2026
₹5,640.00Low, 9 Oct 2026₹9,849.50High, 3 Nov 2025
Market cap
₹14,971 Cr333rd largest listed
P/E
88.3
P/B
17.2
Dividend yield
0.60%
ROE
20.6%
ROCE
24.4%
Debt to equity
0.00
Volume, NSE
7,11847.8% delivered

AstraZeneca Pharma India board of directors

At the end of the quarter to Jun 2026, as the company filed it; changes since are in its announcements.

  • ChairpersonSHILPA DIVEKAR NIRULA
  • Company Secretary and Compliance OfficerTanya Sanish

6 directors3 independent2 executive1 non-executive

  • SHILPA DIVEKAR NIRULA · ChairpersonIndependent · joined Dec 2021 · reappointed Dec 2021 · 54 months as independent · 3 listed boards · 3 as independent · 2 committee seats, 1 as chair
  • REVATHY ASHOKIndependent · joined Dec 2016 · reappointed Dec 2021 · 114 months as independent · 5 listed boards · 5 as independent · 3 committee seats, 5 as chair
  • MONICA WIDHANIIndependent · joined Sep 2024 · reappointed Sep 2024 · 22 months as independent · 4 listed boards · 4 as independent · 3 committee seats, 3 as chair
  • PRAVEEN RAO AKKINEPALLYExecutive · joined Jul 2025 · 1 listed board · 1 committee seat
  • HOOI BIEN CHUAHNon-executive · joined Nov 2023 · 1 listed board · 1 committee seat, 1 as chair
  • BHAVANA AGRAWALExecutive · joined Feb 2024 · 1 listed board · 1 committee seat

An independent director has no business or family tie to the company, its promoters or its managers beyond the seat. Listed boards counts the boards of listed companies the director sits on, this one included, and "as independent" how many of those seats are independent ones. Committee seats are audit and stakeholder committee seats across those companies. Months as independent is filed for independent directors only, whose terms the rules cap. Disqualified is the company's own mark that a director may not serve under company law.

3 directors who left
  • JESUS JAVIER DIAZ-ROPERO ESTESO, left 19 Mar 2026: Others
  • SYLVIA LORENA VARELA RAMON, left 28 Feb 2026: Others
  • SANJEEV KUMAR PANCHAL, left 30 Jun 2025: Others

Committees and meetings

Who sits on each, and how often they met.Board meeting notices and outcomes

  • Board

    • 26 May 20266 of 6 present3 independent · 75 days in between
    • 11 Mar 20265 of 7 present2 independent · 27 days in between
    • 11 Feb 20268 of 8 present3 independent

  • Audit Committee

    Chair MONICA WIDHANI

    SHILPA DIVEKAR NIRULA, REVATHY ASHOK, HOOI BIEN CHUAH

    • 26 May 20264 of 4 present3 independent · 75 days in between
    • 11 Mar 20263 of 4 present2 independent · 27 days in between
    • 11 Feb 20264 of 4 present3 independent

  • Nomination and remuneration committee

    Chair REVATHY ASHOK

    SHILPA DIVEKAR NIRULA, MONICA WIDHANI

    • 26 May 20263 of 3 present3 independent · 75 days in between
    • 11 Mar 20262 of 4 present2 independent · 27 days in between
    • 11 Feb 20263 of 3 present2 independent

  • Stakeholders Relationship Committee

    Chair HOOI BIEN CHUAH

    SHILPA DIVEKAR NIRULA, PRAVEEN RAO AKKINEPALLY, BHAVANA AGRAWAL

    No meeting listed in the filing.

  • Risk Management Committee

    Chair MONICA WIDHANI

    PRAVEEN RAO AKKINEPALLY, BHAVANA AGRAWAL, AMARPREET KAUR AHUJA

    • 11 Feb 20263 of 3 present1 independent

  • Corporate Social Responsibility Committee

    Chair HOOI BIEN CHUAH

    REVATHY ASHOK, PRAVEEN RAO AKKINEPALLY

    • 26 May 20263 of 3 present1 independent

Meetings in the quarter filed and the one before it. The days in between are as the company files them, neither meeting's day counted; the rules allow at most 120. A quorum is the least number of members who must attend for the meeting to decide anything.

Statutory auditor

Named in the results for the quarter to Mar 2026.

  • Price Waterhouse & Co Chartered Accountants LLPPeer-review certificate valid to Nov 2026

A statutory auditor checks the company's accounts and signs its results. Peer review is the accountants' institute's check of an audit firm's own work, which a listed company's auditor must hold a valid certificate of.

AstraZeneca Pharma India AGM and shareholder votes

Each resolution, how the votes went, and how institutions voted apart from the promoters. A postal ballot is a vote by post or online, held without a meeting.AstraZeneca Pharma India dividend history

Postal ballot, 14 Oct 2026

30,902 shareholders on the register on 4 Sep 2026; votes counted by Vijayakrishna K T / NA.The company's voting result (opens in a new tab)

  1. Approval for appointment of Mr. Arun Krishna (DIN: 11876664) as Non-Executive Director of the Company.
    Ordinary
    99.97% for0.03% against

    Against: promoters 0.00% · institutions 0.22% · other public 1.06%

    Turnout: all 84.52% · promoters 100.00% · institutions 96.72% · other public 1.05%

  2. Change of Designation of Ms. Bhavana Agrawal (DIN: 10485441) from Executive Director to Non-Executive Director of the Company.
    Ordinary
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.09% · other public 2.58%

    Turnout: all 84.52% · promoters 100.00% · institutions 96.72% · other public 1.05%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 10 Aug 2026, 5 resolutions

29,932 shareholders on the register on 3 Aug 2026; present: 1 promoter and 41 others; votes counted by Mr. Vijayakrishna K T / NA.The company's voting result (opens in a new tab)

  1. Adoption of the audited financial statements for the year ended March 31, 2026 and the Reports of the Board of Directors and Auditors thereon.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 87.15% · promoters 100.00% · institutions 96.81% · other public 19.69%

  2. Declaration of dividend of Rs. 36/- per share on equity shares for the financial year 2025-26.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 87.15% · promoters 100.00% · institutions 96.81% · other public 19.69%

  3. Appointment of Ms. Bhavana Agrawal (DIN: 10485441) who retires by rotation, and being eligible, offers herself for re-appointment.
    Ordinary
    99.97% for0.03% against

    Against: promoters 0.00% · institutions 0.29% · other public 0.09%

    Turnout: all 87.15% · promoters 100.00% · institutions 96.81% · other public 19.69%

  4. Appointment of Statutory Auditors of the Company.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.01% · other public 0.08%

    Turnout: all 87.15% · promoters 100.00% · institutions 96.81% · other public 19.69%

  5. Re-appointment of Ms. Shilpa Divekar Nirula (DIN: 06619353) as an Independent Director.
    Special
    98.22% for1.78% against

    Against: promoters 0.00% · institutions 17.03% · other public 0.22%

    Turnout: all 87.15% · promoters 100.00% · institutions 96.81% · other public 19.69%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Postal ballot, 11 May 2026, 1 resolution

29,618 shareholders on the register on 3 Apr 2026; votes counted by Mr. Vijayakrishna K.T / NA.The company's voting result (opens in a new tab)

  1. SHIFTING OF THE REGISTERED OFFICE OF THE COMPANY FROM THE STATE OF KARNATAKA TO THE STATE OF MAHARASHTRA AND CONSEQUENTIAL AMENDMENT TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY.
    Special
    99.99% for0.01% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.55%

    Turnout: all 85.09% · promoters 100.00% · institutions 95.49% · other public 11.50%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Postal ballot, 29 Mar 2026, 2 resolutions

29,857 shareholders on the register on 20 Feb 2026; votes counted by Mr. Vijayakrishna K.T / NA.The company's voting result (opens in a new tab)

  1. Approval of Material Related Party Transactions to be entered into by the Company with AstraZeneca UK Limited
    OrdinaryPromoters have an interest in it
    83.06% for16.94% against

    Against: promoters 0.00% · institutions 27.72% · other public 0.10%

    Turnout: all 13.39% · promoters 0.00% · institutions 95.24% · other public 31.81%

  2. Approval of Material Related Party Transactions to be entered into, by the Company with AstraZeneca AB, Sweden
    OrdinaryPromoters have an interest in it
    83.07% for16.93% against

    Against: promoters 0.00% · institutions 27.72% · other public 0.07%

    Turnout: all 13.39% · promoters 0.00% · institutions 95.24% · other public 31.81%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 14 Aug 2025, 6 resolutions

34,097 shareholders on the register on 8 Aug 2025; present: 1 promoter and 38 others; votes counted by Mr. Vijayakrishna K T / NA.The company's voting result (opens in a new tab)

  1. Adoption of financial statements for the year ended March 31, 2025 and the Report of the Auditors’ and Board of Directors’ thereon.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 84.32% · promoters 100.00% · institutions 87.81% · other public 14.85%

  2. Declaration of dividend of Rs. 32/- per share on equity shares for the financial year 2024-25.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 84.32% · promoters 100.00% · institutions 87.82% · other public 14.85%

  3. Appointment of Ms. Hooi Bien Chuah (DIN: 10381891) who retires by rotation, and being eligible, offers herself for re-appointment.
    Ordinary
    99.94% for0.06% against

    Against: promoters 0.00% · institutions 0.75% · other public 0.02%

    Turnout: all 84.32% · promoters 100.00% · institutions 87.81% · other public 14.85%

  4. Appointment of Mr. Praveen Rao Akkinepally (DIN: 11137771) as a Director and the Managing Director of the Company, liable to retire by rotation.
    Ordinary
    99.90% for0.10% against

    Against: promoters 0.00% · institutions 1.27% · other public 0.01%

    Turnout: all 84.32% · promoters 100.00% · institutions 87.81% · other public 14.85%

  5. Appointment of M/s. Makarand M. Joshi & Co. as the Secretarial Auditors of the Company.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 84.32% · promoters 100.00% · institutions 87.79% · other public 14.85%

  6. Ratification of Cost Auditor’s remuneration.
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.01%

    Turnout: all 84.32% · promoters 100.00% · institutions 87.81% · other public 14.85%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Postal ballot, 27 Mar 2025, 2 resolutions

27,284 shareholders on the register on 21 Feb 2025; votes counted by Mr. Vijaykrishna K.T / NA.The company's voting result (opens in a new tab)

  1. Approval of Material Related Party Transactions to be entered into by the Company with AstraZeneca UK Limited
    OrdinaryPromoters have an interest in it
    99.95% for0.05% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.12%

    Turnout: all 13.59% · promoters 0.00% · institutions 93.16% · other public 35.93%

  2. Approval of Material Related Party Transactions to be entered into, by the Company with AstraZeneca AB, Sweden
    OrdinaryPromoters have an interest in it
    99.95% for0.05% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.12%

    Turnout: all 13.59% · promoters 0.00% · institutions 93.16% · other public 35.93%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Postal ballot, 22 Dec 2024, 2 resolutions

The company's voting result (opens in a new tab)

  1. Approval for appointment of Ms. Monica Widhani (DIN:07674403) as Director (Non-Executive and Independent) of the Company
    Special
    99.97% for0.03% against

    Against: promoters 0.00% · institutions 0.23% · other public 0.70%

    Turnout: all 83.29% · promoters 100.00% · institutions 95.49% · other public 3.81%

  2. Approval for appointment of Mr. Jesus Javier Diaz Ropero Esteso (DIN: 10835384) as Director (Non-Executive) of the Company
    Ordinary
    99.96% for0.04% against

    Against: promoters 0.00% · institutions 0.40% · other public 0.38%

    Turnout: all 83.29% · promoters 100.00% · institutions 95.49% · other public 3.78%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

Annual general meeting, 8 Aug 2024, 4 resolutions

Present: 1 promoter and 46 others.The company's voting result (opens in a new tab)

  1. Adoption of Accounts for the year ended March 31, 2024 and the Reports of the Auditor’s and Director’s thereon
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 85.15% · promoters 100.00% · institutions 95.11% · other public 15.37%

  2. Declaration of dividend of Rs. 24/- per share on equity shares for the financial year 2023-24
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 85.16% · promoters 100.00% · institutions 95.16% · other public 15.37%

  3. Consent of members for the appointment of Dr. Sanjeev Kumar Panchal (DIN: 09823879) who retires by rotation, and being eligible, offers himself for re-appointment
    Ordinary
    99.97% for0.03% against

    Against: promoters 0.00% · institutions 0.39% · other public 0.00%

    Turnout: all 85.16% · promoters 100.00% · institutions 95.16% · other public 15.37%

  4. Ratification of Cost Auditor’s remuneration
    Ordinary
    100.00% for0.00% against

    Against: promoters 0.00% · institutions 0.00% · other public 0.00%

    Turnout: all 85.16% · promoters 100.00% · institutions 95.16% · other public 15.37%

For and against are per cent of the votes cast. Turnout is the votes cast as a per cent of the shares each group holds. Institutions are funds, insurers, banks and foreign investors. An ordinary resolution passes with more than half the votes cast, a special one with at least three quarters.

How mutual funds voted

Fund houses must disclose how they vote at every meeting of a company they hold.Funds that hold it

Mutual fund votes, meeting of 10 Aug 2026, 1 fund house so far (houses' deadline to file 15 Oct 2026)

  • Adoption of the audited financial statements for the year ended March 31, 2026 and the Reports of the Board of Directors and Auditors thereon.
    1 for0 against
  • Declaration of dividend of Rs. 36/- per share on equity shares for the financial year 2025-26.
    1 for0 against
  • Appointment of Ms. Bhavana Agrawal (DIN: 10485441) who retires by rotation, and being eligible, offers herself for re-appointment.
    1 for0 against
  • Appointment of Statutory Auditors of the Company.
    1 for0 against
  • Re-appointment of Ms. Shilpa Divekar Nirula (DIN: 06619353) as an Independent Director.
    1 for0 against

Mutual fund votes, meeting of 11 May 2026, 16 fund houses

  • SHIFTING OF THE REGISTERED OFFICE OF THE COMPANY FROM THE STATE OF KARNATAKA TO THE STATE OF MAHARASHTRA AND CONSEQUENTIAL AMENDMENT TO THE MEMORANDUM OF ASSOCIATION OF THE COMPANY.
    16 for0 against
5 earlier meetings

Mutual fund votes, meeting of 29 Mar 2026, 19 fund houses

  • Approval of Material Related Party Transactions to be entered into by the Company with AstraZeneca UK Limited
    Against Angel One Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Kotak Mahindra Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual Fund
    • Angel One Mutual FundDisclosures not in accordance with Related Party Transaction industry standards; No justification for significant shift in limits of Related Party Transactions proposed.
    • Edelweiss Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual FundNon-Compliant with RPT Industry Standards: As per the RPT Industry Standards prescribed pursuant to the regulatory framework of Securities and Exchange Board of India (SEBI), in cases where material Related Party Transactions (RPTs) or material modifications thereto are proposed for shareholders’ approval, the Company is required to provide specific disclosures in the explanatory statement annexed to the Notice of the general meeting. However, the Company has failed to disclose required information as per the RPT Industry Standards mandated by SEBI. Governance and Transparency Concern: Significant Shift between quantum of previous year RPTs and proposed limit, however, no specific justification for the same.
    • Kotak Mahindra Mutual FundThe disclosure made by the Company is in the Notice is not in accordance with the RPT Industry Standards, as the above mentioned information has not been disclosed in the explanatory statements attached to the Notice. The disclosure regarding the basis of arriving at the pricing of the transactions is a material disclosure for shareholders to ascertain the fairness of the transaction. Hence, we do not favour the resolution.
    13 for6 against
  • Approval of Material Related Party Transactions to be entered into, by the Company with AstraZeneca AB, Sweden
    Against Angel One Mutual Fund, Edelweiss Mutual Fund, Groww Mutual Fund, Kotak Mahindra Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual Fund
    • Angel One Mutual FundDisclosures not in accordance with Related Party Transaction industry standards; No justification for significant shift in limits of Related Party Transactions proposed.
    • Edelweiss Mutual Fund, Groww Mutual Fund, Motilal Oswal Mutual Fund, Navi Mutual FundNon-Compliant with RPT Industry Standards: As per the RPT Industry Standards prescribed pursuant to the regulatory framework of Securities and Exchange Board of India (SEBI), in cases where material Related Party Transactions (RPTs) or material modifications thereto are proposed for shareholders’ approval, the Company is required to provide specific disclosures in the explanatory statement annexed to the Notice of the general meeting. However, the Company has failed to disclose required information as per the RPT Industry Standards mandated by SEBI. Governance and Transparency Concern: Significant Shift between quantum of previous year RPTs and proposed limit, however, no specific justification for the same.
    • Kotak Mahindra Mutual FundThe Company has not disclosed the amount of transactions entered into by the Company with both parties during FY 2025-26. Any major shift in the utilisation of the limits should be addressed by the Company with adequate justifications. Since the Company has not addressed the significant shift in RPT limit, We do have governance and transparency concern in this regard. Hence, we do not favour the resolution.
    13 for6 against

Mutual fund votes, meeting of 14 Aug 2025, 18 fund houses

  • Adoption of financial statements for the year ended March 31, 2025 and the Report of the Auditors’ and Board of Directors’ thereon.
    18 for0 against
  • Declaration of dividend of Rs. 32/- per share on equity shares for the financial year 2024-25.
    18 for0 against
  • Appointment of Ms. Hooi Bien Chuah (DIN: 10381891) who retires by rotation, and being eligible, offers herself for re-appointment.
    18 for0 against
  • Appointment of Mr. Praveen Rao Akkinepally (DIN: 11137771) as a Director and the Managing Director of the Company, liable to retire by rotation.
    Against Axis Mutual Fund, Kotak Mahindra Mutual Fund, Mirae Asset Mutual Fund
    • Axis Mutual FundPraveen Rao Akkinepally, 50, has over 20 years of experience across the US, global markets, and India in oncology and biopharmaceuticals. He served as the Head of the Oncology Business Unit at AstraZeneca India before being appointed as the Managing Director, His cash annual remuneration is estimated at ~Rs. 45.7 mn, excluding stock options. He is eligible for stock options and/or Restricted Stock Units (RSUs) granted by any group/ parent company. AstraZeneca Plc., has an RSU scheme under which the qualifying management employees of the company are granted RSUs. These stock units are awarded without any vesting performance conditions. There is no clarity on the quantum/ value of such stock option compensation, and accordingly, we are unable to estimate his total remuneration. Additionally, the company has not disclosed the performance metrics that determine his pay. Given the lack of clarity on his stock-based compensation, we do not support the resolution.
    • Kotak Mahindra Mutual FundPraveen Rao Akkinepally, 50, has over 20 years of experience across the US, global markets, and India in oncology and biopharmaceuticals. He served as the Head of the Oncology Business Unit at AstraZeneca India before being appointed as the Managing Director. His cash annual remuneration is estimated at ~Rs. 45.7 mn, excluding stock options. He is eligible for stock options and/or Restricted Stock Units (RSUs) granted by any group/ parent company. AstraZeneca Plc., has an RSU scheme under which the qualifying management employees of the company are granted RSUs. These stock units are awarded without any vesting performance conditions. There is no clarity on the quantum/ value of such stock option compensation, and accordingly, we are unable to estimate his total remuneration. Additionally, the company has not disclosed the performance metrics that determine his pay. Given the lack of clarity on his stock-based compensation, we do not support the resolution.
    • Mirae Asset Mutual FundAs per advisory recommendation (Passive holding)
    15 for3 against
  • Appointment of M/s. Makarand M. Joshi & Co. as the Secretarial Auditors of the Company.
    18 for0 against
  • Ratification of Cost Auditor’s remuneration.
    18 for0 against

Mutual fund votes, meeting of 27 Mar 2025, 15 fund houses

  • Approval of Material Related Party Transactions to be entered into by the Company with AstraZeneca UK Limited
    15 for0 against
  • Approval of Material Related Party Transactions to be entered into, by the Company with AstraZeneca AB, Sweden
    15 for0 against

Mutual fund votes, meeting of 22 Dec 2024, 13 fund houses

  • Approval for appointment of Ms. Monica Widhani (DIN:07674403) as Director (Non-Executive and Independent) of the Company
    13 for0 against
  • Approval for appointment of Mr. Jesus Javier Diaz Ropero Esteso (DIN: 10835384) as Director (Non-Executive) of the Company
    13 for0 against

Mutual fund votes, meeting of 8 Aug 2024, 12 fund houses

Each resolution counts the houses whose vote was matched to it; the rest are listed last.

  • Adoption of Accounts for the year ended March 31, 2024 and the Reports of the Auditor’s and Director’s thereon
    12 for0 against
  • Declaration of dividend of Rs. 24/- per share on equity shares for the financial year 2023-24
    12 for0 against
  • Consent of members for the appointment of Dr. Sanjeev Kumar Panchal (DIN: 09823879) who retires by rotation, and being eligible, offers himself for re-appointment
    12 for0 against
  • Ratification of Cost Auditor’s remuneration
    11 for0 against
1 proposal not matched to one resolution
  • To approve, Appointment of M/s. Rao, Murthy & Associates, Cost Accountants, Bengaluru, (Firm Registration No. 000065), as Cost Auditors of the Company.
    1 for0 against

Each fund house counted once, from its own disclosure; the reasons are its own words.

Tax disputes

Reported in the filing for the quarter to Jun 2026.

  • Tax disputeDeputy Commissioner of State Tax (Appeal)Since 29 Jun 2020
    Matter will be suitably challenged in due course. The expected overall financial implication cannot be determined at this stage.
    At the filing before: Company has received an appeal order for the financial year 2018-19, wherein certain adjustments initially made by the Assistant Commissioner of State Tax Investigation relating to supplies made by the Company under Patient Access Program, have been upheld by the Deputy Commissioner of State Tax (Appeal). The order was passed by the Deputy Commissioner of State Tax (Appeal). The matter will be challenged before the GST Appellate Tribunal (GSTAT) by filing an appeal.MoreLess

In the company's own words, from its latest governance filing.

Investor complaints and compliance

Quarter by quarter.

Investor complaints received and resolved, the company's own count

  • Received
  • Resolved

Open at the quarter's end

At most 2 complaints open, quarter to Jun 2026.
The board is made up as the listing rules require
Yes
The board has a regular chairperson
Yes
The company has a risk management committee
Yes
The chair is related to the managing director
No
The filing has a part on fines and penalties
No
The filing has a part on tax disputes
Yes
There was a cyber security incident in the quarter
No

The company's own answers in its filing.